One pill to replace three? diabetes combo drug tested

NCT ID NCT07333742

Completed Knowledge-focused Sponsor: LG Chem Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single pill containing three diabetes medicines (gemigliptin, dapagliflozin, and metformin) works the same in the body as taking them separately. Fifty healthy adults took either the combo pill or the separate drugs after a meal, and researchers measured drug levels in their blood. The goal was to see if the combo pill is a good alternative for simplifying diabetes treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemigliptin, Dapagliflozin, Metformin
What this could lead to: If successful, this could allow people with type 2 diabetes to take one pill instead of multiple, simplifying their treatment.
What could go wrong: This is an early-phase study in healthy volunteers, not patients. It only checks how the drugs are absorbed, not if they work better or are safer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FED CONDITIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FED CONDITIONS HEALTHY VOLUNTEER

Contacts and locations

Locations

Seoul National University Hospital

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.